case 3: pd-l1 testing used in triple-negative breast cancer
Published 4 years ago • 389 plays • Length 3:37Download video MP4
Download video MP3
Similar videos
-
4:40
case 3: the use of combination therapy in triple-negative breast cancer
-
5:54
case 3: treatment after progression in triple-negative breast cancer
-
2:26
case 3: metastatic triple-negative breast cancer
-
4:27
analysis of impassion130: pd-l1 testing in advanced tnbc
-
2:24
case 3: managing immune-related adverse effects in tnbc
-
5:45
case 3: atezolizumab/nab-paclitaxel for triple negative breast cancer
-
1:16
the impassion130 trial in metastatic triple-negative breast cancer
-
5:25
investigational pd-l1–targeted immunotherapy safe for patients with triple-negative breast cancer
-
3:57
rationale for checkpoint inhibitors in tnbc
-
20:43
investigational pd-l1–targeted immunotherapy safe for patients with triple-negative breast cancer
-
6:33
case 3: results of the impassion130 trial in metastatic breast cancer
-
6:56
impassion130 trial data on pd-l1 tumors in tnbc
-
1:38
combined analyses of pd-l1 and tils for therapy selection in tnbc
-
1:00
overcoming challenges in treating patients with triple-negative breast cancer
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
4:22
neotripapdl1: dynamics of tils & pd-l1 expression in breast cancer
-
1:17
recognizing subsets of triple-negative breast cancer
-
1:54
the role of dna repair in triple negative breast cancer
-
1:00:46
triple negative breast cancer case panel discussion | 2022 best of breast conference